Clinical Trials Logo

Clinical Trial Summary

Painful Diabetic peripheral Neuropathy Study of Chinese OutPatiEnt (PDN-SCOPE): a multi-center cross-sectional registry study of clinical characteristics and treatment survey of PDN in China


Clinical Trial Description

Painful diabetic peripheral neuropathy (PDN) presents a serious health problem in China. SCOPE is a cross-sectional, multi-centers registry study with a target sample size of 1500 patients who are experiencing PDN. The patients are treated following guideline and local practice. Real-world data including demographics, medical histories, VAS, PHQ, GAD -7 and therapies are collected. The primary objective is to analyze the clinical characteristics of PDN. The secondary objectives include anxiety depression distribution and current treatment status.The SCOPE study will help to find actual clinical manifestation and treatment and improve the overall treatment outcome of Chinese patients with PDN. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03520608
Study type Observational
Source Peking University Third Hospital
Contact Dongsheng Fan
Phone +8601082265024
Email dsfan@sina.com
Status Recruiting
Phase
Start date May 1, 2018
Completion date May 1, 2019

See also
  Status Clinical Trial Phase
Completed NCT01726413 - A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients). Phase 2
Completed NCT03172598 - Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy Phase 2
Terminated NCT01280747 - Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study Phase 4
Completed NCT01455415 - Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain Phase 3